Clinical Trials · NCT00259298

Evaluation of the Effects of Teriparatide on Skeleton Images in Postmenopausal Women With Osteoporosis

CompletedPhase 4Teriparatide (Approved)
Phase
Phase 4
Recruitment status
Completed
Sponsor
Eli Lilly and Company
Enrollment
12
Start date
Nov 2005
Locations
1 site, United Kingdom
Primary endpoint
Change From Baseline in Whole Skeleton Skeletal Plasma Clearance of 99m Technetium Methylene Diphosphonate (99m Tc-MDP) to 18 Months
View Teriparatide compound reference